Personalized Prevention of Gallbladder Cancer

Guest Editors:

Prof. Dr. Justo Lorenzo Bermejo

Statistical Genetics Research Group, Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany

Dr. Dominique Scherer

Statistical Genetics Research Group, Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany

Deadline for manuscript submissions:
20 August 2024

Message from the Guest Editors

Dear Colleagues,

Gallbladder cancer (GBC, ICD-10 diagnosis code C23) is an aggressive malignancy that accounts for the majority of biliary tract tumours, especially in low- and middle-income countries. Resection of tumours confined to the mucosa is currently the only potentially curative treatment, but early diagnosis is difficult because early symptoms are inconspicuous and nonspecific. On the other hand, GBC develops over a long period of time and surgical removal of the gallbladder in individuals at high-risk of GBC or affected by pre-neoplastic lesions offers a good opportunity for personalized GBC prevention.

This Special Issue of the *Journal of Personalized Medicine* aims to highlight the current status and recent developments in the broad field of personalized GBC prevention. Articles on the identification and characterization of novel risk and early disease biomarkers, on the causal mechanisms linking lifestyle, culture and behaviour to GBC development, and on novel opportunities for targeted therapy of incidental tumours are particularly welcome.

Prof. Dr. Justo Lorenzo Bermejo
Dr. Dominique Scherer
Guest Editors

mdpi.com/si/83096

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us